Table 3.
All data presented in percentage terms. * Paclitaxel, Docetaxel, Vinflunine. ● pooled data, EV dosage of 1.25 mg/kg of body weight. ▯ Data only available for n = 125 [41] + 296 [42]. ▼ All cancer types, subgroup with SG dosage of 10 mg/kg of body weight.
| Medication | CT * [42] | D ± R [43] | Erd [44] | EV ● [40,41,42] | SG ▼ [45] | |
|---|---|---|---|---|---|---|
| D + R | D + P | |||||
| Number of patients (n) | 291 | 258 | 265 | 99 | 112 + 125 + 296 | 97 |
| Treatment related AE, % | 91.8 | 85.7 | 84.2 | NA | 93.8 (91.1–95.8) ▯ | 91.8 |
| Treatment related ≥G3 AE, % | 49.8 | 47.7 | 40.8 | 46.0 | 52.3 (47.5–57.0) ▯ | NA |
| Fitness | ||||||
| Asthenia, % | NA | NA | NA | 20.2 | NA | NA |
| ≥G3 asthenia, % | NA | NA | NA | 7.1 | NA | NA |
| Fatigue, % (95% CI) | 22.7 | 39.1 | 36.2 | 32.3 | 43.9 (29.8–58.9) | 47.4 |
| ≥G3 fatigue, % (95% CI) | 4.5 | 6.6 | 6.0 | 2.0 | 5.7 (3.9–8.1) | 8.2 |
| Skin, hair, nail and mucosa | ||||||
| Alopecia, % (95% CI) | 36.4 | 23.6 | 30.6 | 29.3 | 46.3 (42.1–50.6) | 34.0 |
| ≥G3 alopecia, % | 0 | 0 | 0.4 | 0 | 0 | NA |
| Dry mouth, % | NA | NA | NA | 45.5 | NA | NA |
| ≥G3 dry mouth, % | NA | NA | NA | 0 | NA | NA |
| Dry skin, % (95% CI) | NA | NA | NA | 32.3 | 21.9 (17.1–27.7) | NA |
| ≥G3 dry skin, % | NA | NA | NA | 0 | 0 | NA |
| Hand-foot syndrome, % | NA | NA | NA | 23.2 | NA | NA |
| ≥G3 hand-foot syndrome, % | NA | NA | NA | 5.1 | NA | NA |
| Maculopapular rash, % (95% CI) | NA | NA | NA | NA | 20.9 (15.2–27.9) | NA |
| ≥G3 maculopapular rash, % (95% CI) | NA | NA | NA | NA | 6.0 (4.3–8.5) | NA |
| Nail dystrophy, % | NA | NA | NA | 16.2 | NA | NA |
| ≥G3 nail dystrophy, % | NA | NA | NA | 6.1 | NA | NA |
| Pruritus, % (95% CI) | NA | NA | NA | NA | 27.6 (18.7–38.7) | NA |
| ≥G3 pruritus, % (95% CI) | NA | NA | NA | NA | 1.1 (0.5–2.6) | NA |
| Stomatitis, % | NA | 23.3 | 9.1 | 57.6 | NA | NA |
| ≥G3 stomatitis, % | NA | 3.5 | 0 | 10.1 | NA | NA |
| Gastrointestinal and urinary tract | ||||||
| Abdominal pain, % | NA | NA | NA | NA | NA | 22.7 |
| ≥G3 abdominal pain, % | NA | NA | NA | NA | NA | 3.1 |
| Constipation, % | NA | NA | NA | 28.3 | NA | 30.9 |
| ≥G3 constipation, % | NA | NA | NA | 1.0 | NA | 1.0 |
| Decreased appetite/anorexia, % (95% CI) | 23.4 | 22.1 | 17.0 | 38.4 | 38.3 (29.6–47.7) | NA |
| ≥G3 decreased appetite/anorexia, % | 1.7 | 1.6 | 0.4 | 0 | 2.4 (1.3–4.3) | NA |
| Diarrhoea, % (95% CI) | NA | 23.6 | 16.6 | 50.5 | 28.1 (24.5–32.1) | 56.7 |
| ≥G3 diarrhoea, % (95% CI) | NA | 3.1 | 1.1 | 4.0 | 2.9 (1.7–4.8) | 9.3 |
| Dysgeusia, % (95% CI) | NA | NA | NA | 37.4 | 33.5 (23.4–45.4) | NA |
| ≥G3 dysgeusia, % | NA | NA | NA | 1.0 | 0 | NA |
| Nausea, % (95% CI) | 21.6 | 22.1 | 14.0 | 20.2 | 32.3 (21.8–45.0) | 57.7 |
| ≥G3 nausea, % (95% CI) | 1.4 | 0.8 | 0.8 | 1.0 | 1.4 (0.7–3.0) | 2.1 |
| UTI, % | NA | NA | NA | 16.2 | NA | NA |
| ≥G3 UTI, % | NA | NA | NA | 5.1 | NA | NA |
| Vomiting, % | NA | NA | NA | NA | NA | 39.2 |
| ≥G3 vomiting, % | NA | NA | NA | NA | NA | 3.1 |
| Laboratory changes | ||||||
| Anemia, % | 20.3 | 11.6 | 16.2 | 20.2 | NA | 38.1 |
| ≥G3 anemia, % | 7.6 | 1.9 | 5.3 | 4.0 | NA | 11.3 |
| Hyponatremia, % | NA | NA | NA | 12.1 | NA | NA |
| ≥G3 hyponatremia, % | NA | NA | NA | 11.1 | NA | NA |
| Hyperphosphatemia, % | NA | NA | NA | 76.8 | NA | NA |
| ≥G3 hyperphosphatemia, % | NA | NA | NA | 2.0 | NA | NA |
| Leucopenia, % | NA | NA | NA | NA | NA | NA |
| ≥G3 leucopenia, % | NA | NA | NA | NA | NA | NA |
| White blood cell count decrease, % | 10.7 | 6.6 | 7.5 | NA | NA | 17.5 |
| ≥G3 White blood cell count decrease, % | 6.9 | 4.3 | 6.4 | NA | NA | 11.3 |
| Neutrophil count decrease, % | 16.8 | 11.6 | 10.6 | NA | 10.2 (7.7–13.5) | 53.6 |
| ≥G3 Neutrophil count decrease, % | 13.4 | 8.9 | 10.2 | NA | 6.7 (4.7–9.5) | 33.0 |
| Neutropenia, % | 8.2 | 8.5 | 4.2 | NA | NA | NA |
| ≥G3 Neutropenia, % | 6.2 | 6.6 | 2.3 | NA | NA | NA |
| Neutropenia, febrile, % | 5.5 | 9.3 | 6.0 | NA | NA | NA |
| ≥G3 neutropenia, febrile, % | 5.5 | 9.3 | 6.0 | NA | NA | 6.2 |
| Others | ||||||
| PSN, % (95% CI) | 21.3 | NA | NA | NA | 36.1 (32.1–40.2) | NA |
| ≥G3 PSN, % (95% CI) | 2.1 | NA | NA | NA | 2.5 (1.4–4.3) | NA |